Evidence base: Human papillomavirus

A summary of the evidence behind the primary care management of human papillomavirus.

Colposcopy showing a lesion on the cervix caused by HPV (Photograph: SPL)
Colposcopy showing a lesion on the cervix caused by HPV (Photograph: SPL)

Clinical trials

  • Kelly RS, Patnick J, Kitchener HC et al on behalf of the NHSCSP HPV Special Interest Group. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer 2011: 1-6. doi:10.1038/bjc.2011.326.

Cervarix: phase III trials

  • Lehtinen M, Paavonen J, Wheeler CM et al. For the HPV PATRICIA Study Group. Overall efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia grade 3 or greater: end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2011; 13(1): 89-99.
  • Wheeler CM, Castellsague X, Garland SM et al. For the HPV PATRICIA Study Group. Cross-protective efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: end-of-study (4-year) analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2011; 13(1): 100-10.

Gardasil: phase III trials

  • FUTURE II Study Group. Four year efficacy of prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine against low-grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010; 340: c3493.
  • Kjaer SK, Sigurdsson K, Iversen O-E et al. A pooled analysis of continued prophylactic efficacy of quadrivalent HPV (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res 2009; 2: 868-78.

 

[xhead] Curriculum

This topic falls under section 10.1 of the GP curriculum, Women’s Health.

 

[xhead] Online

 

Individual responses to patient questions from an expert panel

 

Provides information for doctors and patients in many European languages

 

  • Dr Szarewski has received conference sponsorship, honoraria and consultancy fees from GSK and Merck, Sharp and Dohme. She is an investigator in two GSK phase III HPV 16/18 vaccine trials
  • Women's Health conference, 27 September 2012, London.

 

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in